[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615786":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":44,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Atlas University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Metastatic Breast Cancer",null,"Participants diagnosed with breast cancer and radiologically confirmed distant metastasis to bone, liver, lung, or brain.",{"label":13,"type":10,"description":14,"interventionNames":10},"Non-Metastatic Early-Stage Breast Cancer","Participants diagnosed with early-stage and local advenced (Stage I-III) breast cancer with no clinical or radiological evidence of distant metastasis.",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Controls","Age-matched healthy individuals without known malignancy or active systemic disease.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Emine Yildirim, MD","CONTACT","+905056234825","opdreyildirim@gmail.com",[25],{"facility":26,"status":27,"city":28,"state":28,"zip":29,"country":30,"countryCode":10,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Atlas University Faculty of Medicine","RECRUITING","Istanbul","34403","Turkey (Türkiye)",{"type":32,"coordinates":33},"Point",[34,35],28.94966,41.01384,{"lat":35,"lon":34},[38,40],{"name":39,"role":21,"phone":22,"phoneExt":10,"email":23},"EMİNE YILDIRIM",{"name":41,"role":21,"phone":42,"phoneExt":10,"email":43},"Hafize Uzun, PhD","90 535 542 11 47","hafize.uzun@atlas.edu.tr",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Emine YILDIRIM","associate professor, MD","100615786","pten-and-organ-specific-micrornas-in-metastatic-breast-cancer-100615786",false,"NCT07297134","PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer","Serum PTEN Levels and Organ-Specific microRNA Signatures as Predictors of Metastatic Patterns in Breast Cancer: A Prospective Observational Study","PTEN-miR-MBC","Inclusion Criteria:\n\n* Female individuals aged ≥18 years\n* Ability to provide written informed consent\n* Group I (Metastatic BC): Histopathologically confirmed breast cancer and radiologically or clinically proven distant organ metastasis at the time of enrollment\n* Group II (Non-Metastatic BC): Histopathologically confirmed breast cancer with no evidence of distant metastasis\n* Group III (Healthy Controls): Women ≥18 years with no known breast disease and no personal history of malignancy\n\nExclusion Criteria:\n\n* History of any other primary malignancy\n* Known breast disease or breast cancer diagnosis in Group III\n* Immunosuppressive therapy that may alter immune or biomarker profiles\n* Active infection or inflammatory condition that may alter biomarker levels\n* Inability or unwillingness to provide informed consent\n* Severe hepatic, renal, or hematologic dysfunction\n* Current pregnancy or lactation",true,"FEMALE","18 Years",{"count":60,"type":61},160,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy controls (n=40).\n\nThe primary objective is to identify serum biomarkers that differentiate metastatic from non-metastatic disease. Secondary analyses will evaluate correlations between biomarker levels and organ-specific metastatic involvement, including bone, lung, liver, and brain metastases. Findings from this study may support the development of a noninvasive serum-based tool for predicting metastatic patterns in breast cancer.",[65,9,66,67],"Breast Cancer","miRNAs","PTEN",[65,9,66,67,69,70,71],"Breast Cancer Biomarkers","Organ Specific Metastasis","miRNA Profiling","2026-01-26",{"date":74,"type":75},"2026-01-27","ACTUAL",{"date":77,"type":75},"2025-12-01",{"date":79,"type":61},"2026-12",{"name":5,"class":6},1]